바로가기  >

Abstract
Background/aim: We explored the prediction of programmed cell death ligand 1 (PD-L1) expression level in non-small cell lung cancer using a machine learning approach with positron emission tomography/computed tomography (PET/CT)-based radiomics.

Patients and methods: A total of 312 patients (189 adenocarcinomas, 123 squamous cell carcinomas) who underwent F-18 fluorodeoxyglucose PET/CT were retrospectively analysed. Imaging biomarkers with 46 CT and 48 PET radiomic features were extracted from segmented tumours on PET and CT images using the LIFEx package. Radiomic features were ranked, and the top five best feature subsets were selected using the Gini index based on associations with PD-L1 expression in at least 50% of tumour cells. The areas under the receiver operating characteristic curves (AUCs) of binary classifications afforded by several machine learning algorithms (random forest, neural network, Naïve Bayes, logistic regression, adaptive boosting, stochastic gradient descent, support vector machine) were compared. The model performances were tested by 10-fold cross validation.

Results: We developed and validated a PET/CT-based radiomic model predicting PD-L1 expression levels in lung cancer. Long run high grey-level emphasis, homogeneity, mean Hounsfield unit, long run emphasis from CT, and maximum standardised uptake value from PET were the five best feature subsets for positive PD-L1 expression. The Naïve Bayes model (AUC=0.712), with a sensitivity of 75.3% and specificity of 58.2%, outperformed all other classifiers. It was followed by the neural network model (AUC=0.711), random forest (AUC=0.700), logistic regression (AUC=0.673) and adaptive boosting (AUC=0.604).

Conclusion: PET/CT-based radiomic features may help clinicians identify tumours with positive PD-L1 expression in a non-invasive manner using machine learning algorithms.

Affiliations

Chae Hong Lim # 1, Young Wha Koh # 2, Seung Hyup Hyun 3, Su Jin Lee 4
1Department of Nuclear Medicine, Soonchunhyang University Hospital, Seoul, Republic of Korea.
2Department of Pathology, Ajou University School of Medicine, Suwon, Republic of Korea.
3Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; suesj202@ajou.ac.kr shnm.hyun@samsung.com.
4Department of Nuclear Medicine, Ajou University School of Medicine, Suwon, Republic of Korea suesj202@ajou.ac.kr shnm.hyun@samsung.com.
#Contributed equally.